Immunosenescence—the natural weakening of the immune system with age—significantly reduces the effectiveness of cancer vaccines. However, despite its clear clinical impact, most vaccine development pipelines fail to incorporate age-related immune changes. Traditional 2D culture systems cannot capture the intricate, age-specific immune interactions, limiting their ability to predict real-world vaccine performance.
A Lymph Node-Inspired Solution
To overcome these limitations, Dr. Jucaud’s team created a lymph node paracortex-inspired organ-on-a-chip platform. This system models essential steps in cancer vaccine-triggered immunity, including antigen presentation, antigen-specific T-cell activation and tumor-targeting cytotoxicity. By directly comparing immune responses from young and older lymphocytes, the platform successfully identifies age-related functional differences that naturally occur in the human body.
Key Discoveries Using the Platform
As reported by medicalxpress, the researchers found that young antigen-presenting cells exhibited markedly stronger peptide presentation than older cells. Consequently, these young cells triggered higher activation of antigen-specific T cells and stronger cancer cell killing. Importantly, the team could detect these age-dependent variations only through the organ-on-a-chip platform, demonstrating its superior ability to reveal biologically meaningful immune differences that conventional 2D models overlook.
“This work introduces our lymph node on-a-chip platform for cancer vaccine testing,” said Dr. Jucaud, Principal Investigator and Assistant Professor at the Terasaki Institute. “Unlike traditional 2D models, this system replicates age-related immune responses. Since older adults face the highest cancer risk and often have diminished immunity, accurately modeling these conditions in vitro offers more reliable insights into vaccine performance and accelerates development.”
Transformative Potential for Cancer Vaccine Research
By faithfully replicating aging immune biology, this platform provides a powerful tool for assessing how immunosenescence affects cancer vaccine efficacy. Ultimately, this technology could guide the design of next-generation immunotherapies tailored to older patients, ensuring that emerging cancer treatments effectively support the populations that need them most.